Clowse, M. E. B., Wolf, D. C., Foerger, F., Cush, J. J., Golembesky, A., Shaughnessy, L., … Mahadevan, U. (2014). Pregnancy Outcomes after Exposure to Certolizumab Pegol: Updated Results from Safety Surveillance. ARTHRITIS & RHEUMATOLOGY, 66, S621–S622.

Clowse, Megan E. B., Douglas C. Wolf, Frauke Foerger, John J. Cush, Amanda Golembesky, Laura Shaughnessy, Dirk De Cuyper, Kristel Luijtens, Sarah Abbas, and Uma Mahadevan. “Pregnancy Outcomes after Exposure to Certolizumab Pegol: Updated Results from Safety Surveillance.” ARTHRITIS & RHEUMATOLOGY 66 (October 1, 2014): S621–22.

Clowse MEB, Wolf DC, Foerger F, Cush JJ, Golembesky A, Shaughnessy L, et al. Pregnancy Outcomes after Exposure to Certolizumab Pegol: Updated Results from Safety Surveillance. ARTHRITIS & RHEUMATOLOGY. 2014 Oct 1;66:S621–2.

Clowse, Megan E. B., et al. “Pregnancy Outcomes after Exposure to Certolizumab Pegol: Updated Results from Safety Surveillance.” ARTHRITIS & RHEUMATOLOGY, vol. 66, WILEY-BLACKWELL, Oct. 2014, pp. S621–22.

Clowse MEB, Wolf DC, Foerger F, Cush JJ, Golembesky A, Shaughnessy L, De Cuyper D, Luijtens K, Abbas S, Mahadevan U. Pregnancy Outcomes after Exposure to Certolizumab Pegol: Updated Results from Safety Surveillance. ARTHRITIS & RHEUMATOLOGY. WILEY-BLACKWELL; 2014 Oct 1;66:S621–S622.